Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Spero Therapeutics, Inc. (SPRO : NSDQ)

• Company Description    Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. Number of Employees: 25

• Price / Volume Information    Yesterday's Closing Price: $1.11 Daily Weekly Monthly 20 Day Moving Average: 489,598 shares Shares Outstanding: 58.24 (millions) Market Capitalization: $64.64 (millions) Beta: 1.50 52 Week High: $3.08 52 Week Low: $1.08 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.20% -10.26% 12 Week -7.50% -9.76% Year To Date -52.36% -56.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 675 Massachusetts Avenue 14th Floor - Cambridge,MA 02139 USA ph: 857-242-1600 fax: - ir@sperotherapeutics.com https://sperotherapeutics.com

• General Corporate Information    Officers Esther Rajavelu - President; Chief Executive Officer; Chief Financia Milind Deshpande - Director Scott Jackson - Director John C. Pottage - Director Cynthia Smith - Director Peer Information Spero Therapeutics, Inc. (CORR.) Spero Therapeutics, Inc. (RSPI) Spero Therapeutics, Inc. (CGXP) Spero Therapeutics, Inc. (BGEN) Spero Therapeutics, Inc. (GTBP) Spero Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 84833T103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/12/26 Share - Related Items Shares Outstanding: 58.24 Most Recent Split Date: (:1) Beta: 1.50 Market Capitalization: $64.64 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.58 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 10.09 PEG Ratio: - Price Ratios Price/Book: 1.45 Price/Cash Flow: 7.30 Price / Sales: 1.06 EPS Growth vs. Year Ago Period: -433.33% vs. Previous Quarter: -23.08% Sales Growth vs. Year Ago Period: -95.61% vs. Previous Quarter: -99.38% ROE 09/30/26 - - 06/30/26 - 16.17 03/31/26 - 35.58 ROA 09/30/26 - - 06/30/26 - 12.57 03/31/26 - 24.95 Current Ratio 09/30/26 - - 06/30/26 - 6.12 03/31/26 - 10.50 Quick Ratio 09/30/26 - - 06/30/26 - 6.12 03/31/26 - 10.50 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - 24.90 Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - 24.90 Pre-Tax Margin 09/30/26 - - 06/30/26 - 16.26 03/31/26 - 25.33 Book Value 09/30/26 - - 06/30/26 - 0.76 03/31/26 - 0.91 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©